We invest in six areas to advance the development and delivery of new HIV prevention methods while improving the efficiency and effectiveness of existing prevention and treatment efforts. We work with an array of partners, including government agencies in donor countries and developing countries, multilateral organizations, nongovernmental organizations (NGOs), academic institutions, community organizations, and private industry.
Vaccine Research and Development
Our largest investment is in efforts to discover and develop an HIV vaccine. Exciting new discoveries and a robust pipeline of promising vaccine concepts have created optimism that a safe and effective vaccine will emerge that can dramatically reduce global HIV incidence. We support the global HIV vaccine pipeline at multiple levels. At the early discovery phase, we invest in an array of vaccine concepts through the foundation’s Grand Challenges Explorations competition. We also provide funding to move novel product concepts toward human clinical trials, including replicating vectors, vaccines to induce mucosal immunity, passive immunization, and the development of immunogens to elicit protective antibodies. And we invest in late-stage clinical trials, such as the Pox-Protein Public Private Partnership (P5), to advance promising candidates toward licensure. To strengthen and accelerate the HIV vaccine field broadly, we invest in research consortia as well as product development and manufacturing platforms.
Anti-Retroviral Prevention Methods
The development of new prevention methods is essential to reducing HIV transmission. We support efforts to develop, evaluate, and introduce innovative approaches to protecting populations who are at risk of HIV infection.
HIV-related information is displayed in a waiting area outside a rural clinic in Kivumu, Rwanda.
These approaches include systemic and topical anti-retroviral compounds and long-acting products such as injections and vaginal rings, which are less dependent on daily user adherence. We are also interested in dual protection methods that combine microbicides with effective contraception.
We also invest in efforts to evaluate the best approaches to enhancing the secondary prevention potential of HIV treatment (i.e., treatment as prevention). Our goal is to help national governments and global partners understand the most efficient and effective approaches to integrating treatment as prevention into broader prevention programs that combine primary preventive interventions such as condoms, male circumcision, and targeted behavioral interventions.
Efficient and Effective Service Delivery
The growth in international funding for HIV has slowed in recent years, but the demand for HIV services has not. About half of all people in need of treatment for HIV do not receive it, and more than 2 million people are newly infected each year. To continue expanding quality treatment and prevention, we must ensure that every investment yields maximum results. To that end, we invest in five interrelated areas to help increase access to HIV services:
- Reducing the cost of essential anti-retroviral treatments by developing better approaches to process chemistry, dose optimization, and manufacturing
- Rigorously evaluating combinations of preventive interventions to determine the most effective combined strategies
- Collaborating with major HIV financing partners to build their capacity to invest in the most effective and cost-effective programs
- Conducting modeling studies to help countries allocate their HIV resources more effectively
- Assessing HIV program management strategies to improve prevention and treatment programs
Voluntary Medical Male Circumcision
Research indicates that widespread male circumcision could play a major role in limiting the spread of HIV in the parts of Sub-Saharan Africa where HIV is highly prevalent. However, insufficient supply and weak demand for male circumcision has limited the preventive impact of this intervention. The foundation invests in male circumcision efforts at two levels: It supports planning and coordination to spur circumcision efforts in 14 target African countries, and it supports the development and introduction of devices that can facilitate nonsurgical, low-cost, and low-tech circumcision.
Improved Diagnostic Methods
The development of rapid, accurate, and low-cost diagnostic tools that can be used at points of care in low-resource settings can greatly enhance the impact of HIV treatment and prevention programs. Devices that deliver rapid HIV diagnosis can help HIV-positive people seek more timely care and treatment. Rapid and accurate tests for CD4 and viral load can help improve patient care. We also support programs to improve the measurement of HIV incidence.
Demonstrating the Scalability of HIV Programs
The foundation has supported national efforts to design and deliver HIV services to high-risk populations in India, China, Myanmar, and Botswana, with the goal of demonstrating the feasibility of delivering effective services on a broad scale. For the past decade, we have worked with national AIDS coordinating organizations, local governments, and community-based NGOs in those four countries to scale up approaches to delivering essential HIV services. India’s Avahan program has demonstrated notable success, with independent evaluations estimating that it has helped prevent more than 100,000 new HIV infections in India. We are working to help transition these programs so they can be administered by national governments and local partners in a sustainable fashion.